EUVIMEDEUVIMED entdecken
Übersichtsarbeit

SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction

Yu An, Haitao Zhang

American Journal of Nephrology · 18.06.2025 · 57 (1) · 53-65

DOI: 10.1159/000546079 ↗

Kurz gefasst

Übersichtsarbeit in der Zeitschrift American Journal of Nephrology, online erschienen am 18.06.2025. Verfasst von Yu An und 1 weiteren Autor:innen. Beteiligte Einrichtung: National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China. Hauptthemen laut MEDLINE: Sodium-Glucose Transporter 2 Inhibitors, Benzhydryl Compounds, Renal Insufficiency, Chronic, Glucosides. Die Arbeit wurde bisher 9-mal zitiert (Crossref) und nennt 74 Literaturangaben.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background: Chronic kidney disease (CKD) is highly prevalent and associated with an increasing burden on patients and the healthcare system. Its complex causes and diverse manifestations pose considerable challenges in slowing disease progression. Over the last few decades, pharmacotherapeutic strategies have primarily focused on reducing albuminuria, managing complications, and alleviating symptoms. Sodium-glucose cotransporter-2 (SGLT-2) inhibitors, known for their glycemic control and cardiovascular benefits in diabetic patients, have shown promise in renal protection, offering hope for slowing CKD progression in a broader patient population. Summary: The DAPA-CKD and EMPA-KIDNEY trials have provided compelling evidence that dapagliflozin and empagliflozin reduced the risk of a series of renal events and slowed the chronic decline of estimated glomerular filtration rate in patients with CKD, irrespective of diabetic status. The results of these trials strongly support the notion that SGLT-2 inhibitors are effective in renal protection across CKD patients with diverse primary diseases and in varying CKD risk categories. EMPA-KIDNEY also demonstrated that empagliflozin can potentially slow CKD progression in patients without albuminuria, a finding corroborated by results from several other studies. The long-term cardiorenal benefits of empagliflozin were further demonstrated in the post-trial follow-up sub-study of EMPA-KIDNEY. The synergistic effect of SGLT-2 inhibitors with other drugs that have different mechanisms of action is being researched for broader applications. Key Messages: Emerging evidence underscores the potential of SGLT-2 inhibitors to benefit a wide range of CKD patients, regardless of causes and albuminuria status. Further research in this area will improve our understanding of the roles of this new class of drug in renal protection and potentially shift the paradigm of CKD management.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Sodium-Glucose Transporter 2 InhibitorsBenzhydryl CompoundsRenal Insufficiency, ChronicGlucosidesDiabetes Mellitus, Type 2Diabetic NephropathiesProteinuriaHumansDisease ProgressionGlycemic ControlGlomerular Filtration Rate

Stichwörter der Autor:innen

Chronic kidney diseaseNonproteinuric kidney diseasesRenal protectionSodium-glucose cotransporter-2 inhibitors

Substanzen

Sodium-Glucose Transporter 2 InhibitorsempagliflozinBenzhydryl CompoundsGlucosidesdapagliflozin

Autor:innen und Institutionen

  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China.
  • National Clinical Research Center for Kidney Diseases, Jinling Hospital, Affiliated Hospital of Medical School, Nanjing University, Nanjing, China, htzhang163@163.com.

Zitieren

APA

An, Y., & Zhang, H. (2025). SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction. American Journal of Nephrology, 57(1), 53-65. https://doi.org/10.1159/000546079

Vancouver

An Y, Zhang H. SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction. American Journal of Nephrology. 2025;57(1):53-65. doi:10.1159/000546079

BibTeX
@article{An2025,
  author = {An, Yu and Zhang, Haitao},
  title = {SGLT-2 Inhibitors: A Deeper Dive into Their Renal Protective Properties beyond Glycemic Control and Proteinuria Reduction},
  journal = {American Journal of Nephrology},
  year = {2025},
  volume = {57},
  number = {1},
  pages = {53--65},
  doi = {10.1159/000546079}
}
Kostenlos starten →